ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신세포암 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년에는 CAGR 6.6%로 9억 5,000만 달러에 달할 것으로 예측됩니다. 향후 맞춤형 의료의 확산, 암 조기 발견에 대한 인식 증가, 암 의료에 대한 헬스케어 투자 증가, 의료 접근성 향상, 새로운 치료법에 초점을 맞춘 임상시험 및 연구의 급증 등이 예측 기간 중 성장을 촉진할 것으로 보입니다. 예측 기간의 주요 동향으로는 정밀진단을 위한 인공지능의 통합, 표적 치료의 개발, 면역 치료의 혁신, 바이오마커 식별 발전, 최소 침습 수술 기술의 채택, 영상 기술의 개선 등이 있습니다.
노인 인구 증가는 신세포암 시장의 성장을 촉진할 것으로 예측됩니다. 일반적으로 65세 이상으로 정의되는 노년층은 헬스케어 및 사회적 요구가 독특한 경우가 많습니다. 이 인구 집단의 성장은 헬스케어의 발전, 영양 상태의 개선, 수명 연장에 기인합니다. 신세포암(RCC)은 노년층에서 점점 더 흔해지고 있으며, 이 그룹에 대한 전문적인 검진 및 치료 접근법의 필요성을 강조하고 있습니다. 예를 들어 2024년 1월 미국 비영리단체인 인구문제연구소의 보고서에 따르면 65세 이상 미국인의 수는 2022년 5,800만 명에서 2050년 8,200만 명으로 47% 증가할 것으로 예측됩니다. 결과적으로 고령화가 신세포암 시장의 성장에 기여하고 있습니다.
신세포암 시장의 기업은 암 진단과 치료를 강화하기 위해 기술 발전, 특히 인공지능(AI)을 활용하는 데 주력하고 있습니다. 신장 생검을 분석하기 위해 고안된 AI 기반 솔루션은 진단 정확도를 높이고, 절차를 간소화하며, 환자 결과를 최적화하기 위해 개발되고 있습니다. 이러한 AI 툴은 머신러닝 알고리즘과 컴퓨터 비전을 사용하여 병리학자 및 신장 전문의가 신장 조직 샘플을 평가할 수 있도록 돕습니다. 예를 들어 2024년 3월 네덜란드에 본사를 둔 소프트웨어 기업 아이오신(Iosin)은 신장 생검 분석을 위한 AI 기반 솔루션인 NephroPath 플랫폼을 발표했습니다. 조직 유형 식별, 간질성 섬유증 측정, 사구체 평가 등을 수행합니다. 이 AI 기반 기술은 신장 병리 바이오마커의 일관성, 상세성, 재현성 있는 스코어링을 보장하고, 기존 스코어링 방법의 한계를 극복하고 관찰자 편견을 줄입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 신세포암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 신세포암 시장 : 성장률 분석
세계의 신세포암 시장 실적 : 규모와 성장, 2019-2024
세계의 신세포암 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 신세포암 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 신세포암 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
클리어 셀 신세포암(RCC)
유두상 신세포암(신세포암)
크로모포브 신세포암(RCC)
세계의 신세포암 시장 : 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
요검사
컴퓨터 단층촬영(CT) 스캔
신장적출술
혈액검사
초음파
생검
세계의 신세포암 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
약
절제
표적치료
화학요법
수술
기타 치료법
세계의 신세포암 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
홈케어
기타 최종사용자
세계의 신세포암 시장, 명세포 신세포암(RCC)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
산발성 명세포 신세포암
유전성 명세포 신세포암
세계의 신세포암 시장, 유두 암의 서브 세분화 신세포암(RCC), 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
1형 유두상 신세포암
2형 유두상 신세포암
세계의 신세포암 시장, 호색성 세균 신세포암(RCC)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
고전적 크로모포브 신세포암
하이브리드 크로모포브 RCC
제7장 지역별·국가별 분석
세계의 신세포암 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 신세포암 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
신세포암 시장 : 경쟁 구도
신세포암 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Bristol Myers Squibb Company
AstraZeneca Plc
Abbott Laboratories
Novartis AG
Fresenius Kabi AG
GSK plc
Takeda Pharmaceutical Company Limited
Amgen Inc.
Viatris Inc.(Mylan N.V.)
Astellas Pharma Inc.
Eisai Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Ipsen Pharma
Cipla Inc.
Hikma Pharmaceuticals PLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
신세포암 시장 2029 : 새로운 기회를 제공하는 국가
신세포암 시장 2029 : 새로운 기회를 제공하는 부문
신세포암 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the renal tubules, which are responsible for filtering waste and producing urine. The cancer develops when kidney cells become abnormal and begin growing uncontrollably, forming a tumor that can impair the kidney's ability to filter waste and produce urine.
The primary types of renal cell carcinoma include clear cell RCC, papillary RCC, and chromophobe RCC. Clear cell RCC is the most common form of kidney cancer, arising in the kidney's blood-filtering tubules. Microscopically, the cancer cells appear clear or pale due to the accumulation of lipids and carbohydrates. Diagnosis typically involves a combination of urine and blood tests, computed tomography (CT) scans, ultrasounds, nephrectomy, and biopsies. Treatment options include surgery, targeted therapies, chemotherapy, ablation, medications, and other methods, serving a variety of settings such as hospitals, specialty clinics, home care, and other healthcare providers.
The renal cell carcinoma market research report is one of a series of new reports from The Business Research Company that provides renal cell carcinoma market statistics, including the renal cell carcinoma industry's global market size, regional shares, competitors with a renal cell carcinoma market share, detailed renal cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the renal cell carcinoma industry. This renal cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The renal cell carcinoma market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of kidney cancer, a growing geriatric population, wider adoption of targeted therapies, enhanced awareness of cancer screening, improvements in healthcare infrastructure, and a rise in investments in oncology research and development.
The renal cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Looking forward, the growth in the forecast period is expected to be driven by the growing adoption of personalized medicine, increasing awareness about early cancer detection, rising healthcare investments in oncology, better access to healthcare, and a surge in clinical trials and research focused on novel therapies. Key trends for the forecast period include the integration of artificial intelligence for precision diagnostics, the development of targeted therapies, innovations in immunotherapy, advancements in biomarker identification, the adoption of minimally invasive surgical techniques, and improvements in imaging technologies.
The increasing geriatric population is anticipated to drive the expansion of the renal cell carcinoma market. The elderly, typically defined as individuals aged 65 and above, often have unique healthcare and social needs. The growth in this demographic is attributed to advancements in healthcare, improved nutrition, and longer life expectancy. Renal cell carcinoma (RCC) is becoming more common among older adults, underscoring the need for specialized screening and treatment approaches for this group. For example, in January 2024, a report by the Population Reference Bureau, a US-based non-profit organization, predicted that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the aging population is contributing to the growth of the renal cell carcinoma market.
Companies in the renal cell carcinoma market are focusing on technological advancements, particularly in the use of artificial intelligence (AI) to enhance cancer diagnosis and treatment. AI-powered solutions, such as those designed to analyze kidney biopsies, are being developed to improve diagnostic accuracy, streamline procedures, and optimize patient outcomes. These AI tools use machine learning algorithms and computer vision to assist pathologists and nephrologists in evaluating kidney tissue samples. For example, in March 2024, Aiosyn, a software company based in the Netherlands, introduced the NephroPath platform, an AI-powered solution for kidney biopsy analysis. NephroPath employs computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and assessing glomeruli. This AI-driven technology ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, addressing limitations of traditional scoring methods and reducing observer bias.
In October 2024, Arcus Biosciences, a US-based biotechnology firm, partnered with AstraZeneca plc to investigate the combination of casdatifan (AB521) and volrustomig for patients with clear cell renal cell carcinoma (ccRCC). The partnership aims to advance treatment for ccRCC by developing a new drug combination, combining the expertise of both companies to accelerate development and improve patient outcomes. AstraZeneca plc, a UK-based pharmaceutical company, is known for its focus on oncology treatments and diagnoses.
Major players in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics.
North America was the largest region in the renal cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renal cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the renal cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The renal cell carcinoma market consists of revenues earned by entities by providing services such as CT scans, ultrasounds, chemotherapy and targeted therapy, immunotherapy, and supportive care and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal cell carcinoma market also includes sales of needle biopsy systems, laser ablation devices, biopsy trays and kits, and biopsy specimen containers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Renal Cell Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on renal cell carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for renal cell carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal cell carcinoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Renal Cell Carcinoma Market Characteristics
3. Renal Cell Carcinoma Market Trends And Strategies
4. Renal Cell Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Renal Cell Carcinoma Growth Analysis And Strategic Analysis Framework
5.1. Global Renal Cell Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Renal Cell Carcinoma Market Growth Rate Analysis
5.4. Global Renal Cell Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Renal Cell Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Renal Cell Carcinoma Total Addressable Market (TAM)
6. Renal Cell Carcinoma Market Segmentation
6.1. Global Renal Cell Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clear Cell Renal Cell Carcinoma (RCC)
Papillary Renal Cell Carcinoma (RCC)
Chromophobe Renal Cell Carcinoma (RCC)
6.2. Global Renal Cell Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine Tests
Computed Tomography (CT) Scan
Nephrectomy
Blood Tests
Ultrasound
Biopsy
6.3. Global Renal Cell Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medication
Ablation
Targeted Therapy
Chemotherapy
Surgery
Other Treatments
6.4. Global Renal Cell Carcinoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users
6.5. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Clear Cell Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sporadic Clear Cell RCC
Hereditary Clear Cell RCC
6.6. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Papillary Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 1 Papillary RCC
Type 2 Papillary RCC
6.7. Global Renal Cell Carcinoma Market, Sub-Segmentation Of Chromophobe Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Classic Chromophobe RCC
Hybrid Chromophobe RCC
7. Renal Cell Carcinoma Market Regional And Country Analysis
7.1. Global Renal Cell Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Renal Cell Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
